title: Tigecycline penetration into skin and soft tissue.
abstract: BACKGROUND
  Tigecycline, a derivative of minocycline, has antibacterial activity against common pathogens associated with complicated skin and soft tissue infections (cSSTIs), including methicillin-resistant Staphylococcus aureus. At present, there is a paucity of data concerning its penetration into skin and soft tissue (SST).
  
  
  METHODS
  This study evaluated the penetration of tigecycline into SST in 25 patients (mean age, 52 years) with cSSTIs requiring surgical intervention. After a 100-mg loading dose, each patient received 50 mg of tigecycline infused intravenously over 1 h every 12 h. Blood samples were obtained on the day of surgery at 1 h (peak), during surgery, and 12 h (trough) after the beginning of a 50-mg infusion. A viable SST sample was harvested at the infection site. Tissue and concomitant serum concentrations were grouped into three time intervals: 2-4 h (median, 3 h), 5-7 h (median, 7 h), and 8-10 h (median, 9h), and analyzed for tissue penetration.
  
  
  RESULTS
  Tissue and blood samples were obtained one to six days (mean 2.5 days) after initiation of tigecycline treatment. The mean serum peak and trough concentrations of tigecycline were 0.56±0.25 mg/L and 0.26±0.12 mg/L, respectively. The mean tissue:serum ratios at the three study time periods were 3.8 (range 0.7-5.5), 5.2 (range 0.8-7.1), and 2.8 (range 0.8-8.8).
  
  
  CONCLUSIONS
  In general, we found higher concentrations of tigecycline in SST than in the serum at the same time point.
authors.affiliation: Department of Medicine, Michigan State University , East Lansing, Michigan, USA. steing@msu.edu
authors.forename: Gary E
authors.initials: GE
authors.lastname: Stein
authors.forename: Curtis L
authors.initials: CL
authors.lastname: Smith
authors.forename: Anne
authors.initials: A
authors.lastname: Missavage
authors.forename: James P
authors.initials: JP
authors.lastname: Saunders
authors.forename: David P
authors.initials: DP
authors.lastname: Nicolau
authors.forename: Stephanie M
authors.initials: SM
authors.lastname: Battjes
authors.forename: John P
authors.initials: JP
authors.lastname: Kepros
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003238:Connective Tissue / Q000378:metabolism; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D012867:Skin / Q000378:metabolism; D017192:Skin Diseases, Bacterial / Q000188:drug therapy* / Q000378:metabolism; D018461:Soft Tissue Infections / Q000188:drug therapy* / Q000378:metabolism; D000078304:Tigecycline
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline